Melbourne, Australia; Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) will participate later today in the ASX Spotlight New York event.

Starpharma is one of 15 ASX listed companies to be featured at the event, which is held annually to showcase emerging Australian companies before US institutional investors.

CEO Dr Jackie Fairley will present at the event, which is in its seventh year and is attended by more than 240 investors.

“Starpharma welcomes this opportunity to speak to the Company’s recent achievements and to build on an already strong and international institutional investor base,” said CEO Dr Jackie Fairley.

There is an opportunity for one-on-one meetings in addition to the Company’s formal presentation, which will provide an overview of Starpharma’s business and portfolio including:

• Starpharma’s lead product, VivaGel^® for the management and prevention of bacterial vaginosis, as a late-stage clinical asset.
• Two attractive commercial licenses for VivaGel^®-coated condom: Ansell and Okamoto.
• Commencement of a Phase 1 clinical trial of DEP™ docetaxel and latest preclinical results for DEP™ oxaliplatin.
• An update on the agrochemical program, including internal development of a dendrimer-enhanced version of glyphosate (Roundup^®).

Download the ASX Announcement and Presentation: Starpharma to present to US institutional investors ( pdf file, 2MB)